Quoin Pharmaceuticals raises up to $50m in private placement

Quoin Pharmaceuticals has secured up to $50 million through a private placement with a group of healthcare-focused institutional investors, providing the NASDAQ-listed company with capital to complete late-stage clinical development of its lead candidate, QRX003, in Netherton Syndrome.

The financing, expected to close on or around 31 August 2026, consists of approximately $30.8 million in upfront proceeds from the issuance of 6,305,300 American Depositary Shares (or pre-funded warrants in lieu thereof), priced at $4.88 per ADS. An additional $19.2 million may follow if investors elect to exercise accompanying ordinary warrants at $6.10 per ADS. Those warrants are immediately exercisable and expire either five years from closing or 30 days after Quoin publicly announces that the primary endpoint has been met in its ongoing QRX003 trial, whichever comes sooner.

Named participants include Sirenia Capital Management, Sphera Healthcare, AIGH Capital Management, Nantahala Capital, StemPoint Capital and Stonepine Capital Management, alongside members of Quoin's management team and board. Leerink Partners is serving as lead placement agent, with BTIG and Lake Street Capital Markets acting as co-agents.

Use of proceeds and pipeline context

Quoin said it intends to deploy the upfront net proceeds on general corporate purposes, including operating expenses, research and development, and completion of the QRX003 clinical programme. The company added that aggregate net proceeds, assuming full warrant exercise, would be sufficient to fund operations into the second half of 2029. That runway gives the company meaningful headroom to report topline data from its pivotal trial without requiring a bridge financing.

QRX003 targets Netherton Syndrome, a severe, chronic inflammatory skin disorder caused by loss-of-function mutations in the SPINK5 gene. The condition is estimated to affect fewer than one in 200,000 individuals and currently has no approved systemic treatment. Quoin's platform also spans candidates for Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, as well as vascular malformations and angiofibromas.

Market landscape and regulatory read-across

Rare inflammatory skin conditions represent a relatively uncrowded segment of the specialty dermatology market, though momentum has been building. The approval of biologics for atopic dermatitis over the past decade has validated the category commercially, and regulators have shown a willingness to grant Breakthrough Therapy and Orphan Drug designations to sponsors addressing conditions with no approved therapies. Quoin has not disclosed whether QRX003 holds any such designation, which would be a key piece of context for investors assessing the regulatory path to a potential NDA.

The warrant structure is notable: tying the expiry of ordinary warrants to a binary clinical event creates a direct financial incentive for investors aligned with trial success, but it also concentrates dilution risk around the same readout window that will determine the programme's value. That kind of milestone-linked instrument has become more common in small-cap biotech private placements over the past two years, as companies seek to lower upfront dilution while still offering downside-protected upside to specialist funds.

Quoin trades on NASDAQ under the ticker QNRX. The company has agreed to file a resale registration statement with the SEC covering the ADSs issued in the placement and those underlying the warrants.